Abstract
The chapter on miscellaneous antibiotics reviews the drug interactions with antibiotics such as chloramphenicol, tetracycline, and the aminoglycosides which are older agents that are less frequently prescribed, so many clinicians may not be familiar with their interactions with other medications. It also reviews the interactions with tigecycline and quinupristin-dalfopristin, two agents that are the only available agents from classes of antibiotics that are used clinically today. Many of the interactions reviewed such as with linezolid are based on single case reports or a limited series of patients. This chapter serves as a convenient resource for the drug interactions associated with these older antibiotics and as a compilation of the multiple case reports of drug interactions with antibiotics such as linezolid.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Spika JS, Davis DJ, Martin SR et al (1986) Interaction between chloramphenicol and acetaminophen. Arch Dis Child 61:1211–1124
Kearns GL, Bocchini JA, Brown RD et al (1985) Absence of a pharmacokinetic interaction between chloramphenicol and acetaminophen in children. J Pediatr 107:134–139
Stein CM, Thornhill DP, Neill P et al (1989) Lack of effect of paracetamol on the pharmacokinetics of chloramphenicol. Br J Clin Pharmacol 27:262–264
Bloxham RA, Durbin GM, Johnson T et al (1979) Chloramphenicol and phenobarbitone Na drug interaction. Arch Dis Child 54:76–77
Powell DA, Nahata MC, Durrell DC et al (1981) Interactions among chloramphenicol, phenytoin, and phenobarbital in a pediatric patient. J Pediatr 98:1001–1003
Koup JR, Gibaldi M, McNamara P et al (1987) Interaction of chloramphenicol with phenytoin and phenobarbital. Clin Pharmacol Ther 24:571–575
Ballek RE, Reidenberg MM, Orr L (1973) Inhibition of diphenylhydantoin metabolism by chloramphenicol. Lancet 1:150
Greenlaw CW (1979) Chloramphenicol-phenytoin interaction. Drug Intell Clin Pharm 13:609–610
Saltiel M, Stephens NM (1980) Phenytoin-chloramphenicol interaction. Drug Intell Clin Pharm 14:221
Christensen LK, Skovsted L (1969) Inhibition of metabolism by chloramphenicol. Lancet 2:1397–1399
Brunova E, Slabochova Z, Platilova H et al (1977) Interaction of tolbutamide and chloramphenicol in diabetic patients. Int J Clin Pharmacol 15:7–12
Petitpierre B, Fabre J (1970) Chlorpropamide and chloramphenicol. Lancet 1:789
Wallace JF, Smith RH, Garcia M et al (1967) Studies on the pathogenesis of meningitis. VI. Antagonism between penicillin and chloramphenicol in experimental pneumococcal meningitis. J Lab Clin Med 70:408–418
Jawetz E (1968) The use of combinations of antimicrobial drugs. Annu Rev Pharmacol 8:151–170
Deritis F, Giammanco G, Manzillo G (1972) Chloramphenicol combined with ampicillin in treatment of typhoid. Br Med J 4:17–18
French GL, Ling TKW, Davies DP et al (1985) Antagonism of ceftazidime by chloramphenicol in vitro and in vivo during treatment of gram negative meningitis. Br Med J 291:636–637
Prober CG (1985) Effect of rifampin on chloramphenicol levels. N Engl J Med 312:788–789
Kelly HW, Couch RC, Davis RL et al (1988) Interaction of chloramphenicol and rifampin. J Pediatr 112:817–820
Koch-Weser J, Sellars EM (1971) Drug interactions with coumarin anticoagulants (first of two parts). N Engl J Med 285:487–498
Koch-Weser J, Sellars EM (1971) Drug interactions with coumarin anticoagulants (second of two parts). N Engl J Med 285:547–558
Finegold SM (1970) Interaction of antimicrobial therapy and intestinal flora. Am J Clin Nutr 23:1466–1471
Klippel AP, Pitsinger B (1968) Hypoprothrombinemia secondary to antibiotic therapy and manifested by massive gastrointestinal hemorrhage. Arch Surg 96:266–268
Bui LL, Huang DD (1999) Possible interaction between cyclosporine and chloramphenicol. Ann Pharmacother 33:252.253
Steinfort CL, McConachy KA (1994) Cyclosporin-chloramphenicol drug interaction in a heart-lung transplant patient. Med J Aust 161:455
Mathis AS, Shah N, Knipp GT et al (2002) Interaction of chloramphenicol and the calcineurin inhibitors in renal transplant patients. Transplant Infect Dis 4:169–174
Schulman SL, Shaw LM, Jabs K et al (1998) Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. Transplantation 65:1397–1398
Taber DJ, Dupuis RE, Hollar KD et al (2000) Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient. Transplant Proc 32:660–662
Bakri R, Breen C, Maclean D et al (2003) Serious interaction between tacrolimus FK506 and chloramphenicol in a kidney-pancreas transplant recipient. Transpl Int 16:441–443
Hafner V, Albermann N, Haefeli WE et al (2008) Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis. Antimicrob Agents Chemother 52:4172–4174
Becker LD, Miller RD (1976) Clindamycin enhances a nondepolarizing neuromuscular blockade. Anesthesiology 45:84–87
Best JA, Marashi AH, Pollan LD (1999) Neuromuscular blockade after clindamycin administration: a case report. J Oral Maxillofac Surg 57:600–603
al Ahdal O, Bevan DR (1995) Clindamycin-induced neuromuscular blockade. Can J Anaesth 42:614–617
Sloan PA, Rasul M (2002) Prolongation of rapacuronium neuromuscular blockade by clindamycin and magnesium. Anesth Analg 94:123–124
Rubbo JT, Sokoll MD, Gergis SD (1977) Comparative neuromuscular effects of lincomycin and clindamycin. Anesth Analg 56:329–332
Wright JM, Collier B (1976) Characterization of the neuromuscular block produced by clindamycin and lincomycin. Can J Physiol Pharmacol 54:937–944
Fiekers J, Henderson F, Marshall I et al (1983) Comparative effects of clindamycin and lincomycin on end-plate currents and quantal content at the neuromuscular junction. J Pharmacol Exp Ther 227:308–315
Atchinson W, Adgate L, Beaman C (1988) Effects of antibiotics on the uptake of calcium into isolated nerve terminals. J Pharmacol Exp Ther 245:394–401
Butkus DE, de Torrente A, Terman DS (1976) Renal failure following gentamicin in combination with clindamycin. Nephron 17:307–313
Fruscio R, Lissoni AA, Frapolli R et al (2006) Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients. Cancer Chemother Pharmacol 58:319–325
Curis E, Pestre V, Jullien V et al (2015) Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentrations in patients with bone and joint infections. Infection 43:473–481
Zeller V, Dzeing-Ella A, Kitzis MD et al (2010) Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. Antimicrob Agents Chemother 54:88–92
Bernard A, Kermarrec G, Parize P et al (2015) Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with oral clindamycin-rifampicin combination. J Infect 71:200–206
Wynalda MA, Hutzler JM, Koets MD et al (2003) In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos 31:878–887
Tilstone WJ, Gray JM, Nimmo-Smith RH et al (1977) Interaction between warfarin and sulphamethoxazole. Postgrad Med J 53:388–390
Kaufman JM, Fauver HE (1980) Potentiation of warfarin by trimethoprim-sulfamethoxazole. Urology 16:601–603
Greenlaw CW (1979) Drug interaction between co-trimoxazole and warfarin. Am J Hosp Pharm 36:1155
Errick JK, Keys PW (1978) Co-trimoxazole and warfarin: case report of an interaction. Am J Hosp Pharm 35:1399–1401
O'Reilly RA, Motley CH (1979) Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans. Ann Intern Med 91:34–36
O'Reilly RA (1980) Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphism of racemic warfarin in man. N Engl J Med 302:33–35
Beest P-v, Koerselman J, Herings RMC (2008) Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants. J Thromb Haemost 6:284–290
Lane MA, Zeringue A, McDonald JR (2014) Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans. Am J Med 127:657–663
Ahmed A, Stephens JC, Kaus CA et al (2008) Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin. J Throm Thrombolysis 26:44–48
Schalekamp T, van Geest-Daalderop JHH, MHH K et al (2007) Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. Eur J Clin Pharmacol 63:335–343
Parekh TM, Raji M, Lin YL et al (2014) Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. JAMA Int Med 174:1605–1612
Tan A, Holmes HM, Kuo YF et al (2015) Co-administration of co-trimoxazole with sulfonylureas: hypoglycemia events and pattern of use. J Gerontol A Biol Sci Med Sci 70:247–254
Schelleman H, Bilker WB, Brensinger CM et al (2010) Anti-infective and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin Pharmacol Ther 88:214–222
Juurlink DN, Mamdani M, Kopp A et al (2003) Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289:1652–1658
Alappan R, Perazella MA, Buller GK (1996) Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Int Med 124:316–320
Alappan R, Buller GK, Perazella MA (1999) Trimethoprim-sulfamethoxazole therapy in outpatients: is hyperkalemia a significant problem? Am J Nephrol 19:389–394
Nguyen AT, Gentry CA, Furrh RZ (2013) A comparison of adverse drug reactions between high- and standard-dose trimethoprim-sulfamethoxazole in the ambulatory setting. Curr Drug Saf 8:114–119
Gentry CA, Nguyen AT (2013) An evaluation of hyperkalemia and serum creatinine elevations associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications. Ann Pharmacother 47:1618–1626
Velazquez H, Perazella MA, Wright FS et al (1993) Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 119:296–301
Fralick M, Macdonald EM, Gomes T et al (2014) Co-trimoxazole and sudden cardiac death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ 349:g6196. https://doi.org/10.1136/bmj.g6196
Lee SW, Park SW, Kang JM (2014) Intraoperative hyperkalemia induced by administration of TMP-SMX in a patient receiving angiotensin receptor blockers. J Clin Anesth 26:427–428
Antoniou T, Hollands S, Macdonald EM et al (2015) Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone. CMAJ 187:E138–E142
Pierce D, Corcoran M, Martin P et al (2014) Effect of mmx mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin xr, metronidazole, and sulfamethoxazole: results from four randomized clinical trials. Drug Des Devel Ther 8:529–543
Cudmore J, Seftel M, Sisler J et al (2014) Methotrexate and trimethoprim-sulfamethoxazole. Toxcity from this combination continues to occur. Can Fam Physician 60:53–56
Davis SA, Krowchuk DP, Feldman SR (2014) Prescriptions for a toxic combination: use of methotrexate plus trimethoprim-sulfamethoxazole in the United States. South Med J 107:292–293
Green M, Otieno K, Katana A et al (2016) Pharmacokinetics of mefloquine and its effect on sulfamethoxazole and trimethoprim steady-state blood levels in intermittent preventive treatment (IPTp) of pregnant HIV-infected women in Kenya. Malar J 17:7. https://doi.org/10.1186/s12936-015-1049-9
Jaffe JM, Colonize JL, Pouts RI et al (1973) Effect of altered urinary pH on tetracycline and doxycycline excretion in humans. J Pharmacokinet Bipolar 1:267–282
Jaffe JM, Pouts RL, Fled SL et al (1974) Influence of repetitive dosing and altered pH on doxycycline excretion in humans. J Pharm Sci 63:1256–1260
Chin TF, Latch JL (1975) Drug diffusion and bioavailability: tetracycline metallic chelation. Am J Hosp Pharm 32:625–529
Ericsson CD, Feldman S, Pickering LK et al (1982) Influence of subsalicylate bismuth on absorption of doxycycline. JAMA 247:2266–2267
Albert KS, Welch RD, Descanted KA et al (1979) Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture. J Pharm Sci 68:586–588
Friedman H, Greenbelt DJ, Leduc BW (1989) Impaired absorption of tetracycline by colestipol is not reversed by orange juice. J Clin Pharmacol 29:748–751
Lindenbaum J, Round DG, Butler VP et al (1981) Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 305:789–794
Penttilla O, Neuvonen PJ, Ahoy K et al (1974) Interaction between doxycycline and some anti- epileptic drugs. Br Med J 2:470–472
Neuvonen PJ, Penttilla O, Lehtovaara R et al (1975) Effect of antiepileptic drugs on the elimination of various tetracycline derivatives. Eur J Clin Pharmacol 9:147–154
Neuvonen PJ, Penttila O (1974) Interaction between doxycycline and barbiturates. Br Med J 1:535–536
Westfall LK, Mintzer DL, Wiser TH (1980) Potentiation of warfarin by tetracycline. Am J Hosp Pharm 37:1620–1625
Caraco Y, Rubinow A (1992) Enhanced anticoagulant effect of coumarin derivatives induced by doxycycline coadministration. Ann Pharmacother 26:1084–1086
McGennis AJ (1978) Lithium carbonate and tetracycline interaction. Br Med J 1:1183
Dowd MB, Kippes KA, Witt DM et al (2012) A randomized controlled trial of empiric warfarin dose reduction with the initiation of doxycycline therapy. Thromb Res 130:152–156
Fankhauser MP, Lindon JL, Connolly B et al (1988) Evaluation of lithium-tetracycline interaction. Clin Pharm 7:314–317
Steele M, Couturier JA (1999) possible tetracycline-risperidone-sertraline interaction in an adolescent. Can J Clin Pharmacol 6:15–17
McCormack JP, Reid SE, Lawson LM (1990) Theophylline toxicity induced by tetracycline. Clin Pharm 9:546–549
Kawai M, Honda A, Yoshida H et al (1992) Possible theophylline-minocycline interaction. Ann Pharmacother 26:1300–1301
Pfeifer HJ, Greenblatt DJ, Friedman P (1979) Effects of three antibiotics on theophylline kinetics. Clin Pharmacol Ther 26:36–40
Mathis JW, Prince RA, Weinberger MM et al (1982) Effect of tetracycline hydrochloride on theophylline kinetics. Clin Pharm 1:446–448
Gotz VP, Ryerson GG (1986) Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease. Drug Intell Clin Pharm 20:694–697
Jonkman JHG, van der Boon WJV, Schoenmaker R et al (1985) No influence of doxycycline on theophylline pharmacokinetics. Ther Drug Monit 7:92–94
Bacon JF, Shenfield GM (1980) Pregnancy attributable to interaction between tetracycline and oral contraceptives. Br Med J 280:293
DeSano EA, Hurley SC (1982) Possible interactions of antihistamines and antibiotics with oral contraceptive effectiveness. Fertil Steril 37:853–854
Helms SE, Bredle DL, Zajic J et al (1997) Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol 36:705–710
Neely JL, Abate M, Swinkler M et al (1991) The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone. Obstet Gynecol 77:416–420
Murphy AA, Zacur HA, Charache P et al (1991) The effect of tetracycline on levels of oral contraceptives. Am J Obstet Gynecol 164:28–33
Dogterom P, van den Heuvel MW, Thomsen T (2005) Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomized trials. Clin Pharmacokinet 44:429–438
Archer JS, Archer DF (2002) Oral contraceptive efficacy and antibiotic interaction; a myth debunked. J Am Acad Dermatol 46:917–923
Tortajada-Ituren JJ, Ordovas-Baines JP, Llopis-Salvia P et al (1999) High-dose methotrexate-doxycycline interaction. Ann Pharmacother 33:804–808
Turck M (1984) Successful psoriasis treatment then sudden "cytotoxicity.". Hosp Pract 19:175,6
Colmenero JD, Fernandez-Gallardo LC, Agundez JAG et al (1994) Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. Antimicrob Agents Chemother 38:2798–2802
Zimmerman JJ, Raible DG, Harper DM et al (2008) Evaluation of potential tigecycline-warfarin drug interaction. Pharmacotherapy 28:895–905
Stumpf AN, Schmidt C, Hiddemann W et al (2009) High serum concentrations of ciclosporin related to administration of tigecycline. Eur J Clin Pharmacol 65:101–103
Srinivas NR (2009) Tigecycline and cyclosporine interaction-an interesting case of biliary –excreted drug enhancing the oral bioavailability of cyclosporine. Eur J Clin Pharmacol 65:543–544
Pavan M, Chaudhari AP, Ranganth R et al (2011) Altered bioavailability of tacrolimus following intravenous administration of tigecycline. Am J Kid Dis 57:352
Churchill DN, Seely J (1977) Nephrotoxicity associated with combined gentamicin-amphotericin B therapy. Nephron 19:176–181
Kroenfeld MA, Thomas SJ, Turndorf H (1986) Recurrence of neuromuscular blockade after reversal of vecuronium in a patient receiving polymyxin/amikacin sternal irrigation. Anesthesiology 65:93–94
Warner WA, Sanders E (1971) Neuromuscular blockade associated with gentamicin therapy. JAMA 215:1153–1154
Levanen J, Nordman R (1975) Complete respiratory paralysis caused by a large dose of streptomycin and its treatment with calcium chloride. Ann Clin Res 7:47–49
Lippmann M, Yang E, Au E et al (1982) Neuromuscular blocking effects of tobramycin, gentamicin, and cefazolin. Anesth Analg 61:767–770
Duouis JY, Martin R, Tetrault JP (1989) Atracurium and vecuronium interaction with gentamicin and tobramycin. Can J Anaesth 36:407–411
Singh YN, Marshall IG, Harvey AL (1982) Pre- and postjunctional blocking effects of aminoglycoside, polymyxin, tetracycline and lincosamide antibiotics. Br J Anaesth 54:1295–1306
Zarfarin Y, Koren G, Maresky D et al (1985) Possible indomethacin-aminoglycoside interaction in preterm infants. J Pediatr 106:511–513
Termeer A, Hoitsma AJ, Koene RAP (1986) Severe nephrotoxicity caused by the combined use of gentamicin and cyclosporine in renal allograft recipients. Transplantation 42:220–221
Christensen ML, Stewart CF, Crom WR (1989) Evaluation of aminoglycoside disposition in patients previously treated with cisplatin. Ther Drug Monit 11:631–636
Gonzalez-Vitale JC, Hayes DM, Cvitkovic E et al (1978) Acute renal failure after cis-dichlorodiammineplatinum (II) and gentamicin-cephalothin therapies. Cancer Treat Rep 62:693–698
Salem PA, Jabboury KW, Khalil MF (1982) Severe nephrotoxicity: a probable complication of cis-dichlorodiammineplatinum (II) and cephalothin-gentamicin therapy. Oncology 39:31–32
Kohn S, Fradis M, Podoshin L et al (1997) Ototoxicity resulting from combined administration of cisplatin and gentamicin. Laryngoscope 107:407–408
Dentino M, Luft FC, Yum MN et al (1978) Long-term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 41:1274–1281
Lee EJ, Egorin MJ, Van Echo DA et al (1988) Phase I and pharmacokinetic trial of carboplatin in refractory adult leukemia. J Natl Cancer Inst 80:131–135
Bregman CL, Williams PD (1986) Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin. Cancer Chemother Pharmacol 18:117–123
Kaka JS, Lyman C, Kilarski DJ (1984) Tobramycin-furosemide interaction. Drug Intell Clin Pharm 18:235–238
Mathog RH, Klein WJ (1969) Ototoxicity of ethacrynic acid and aminoglycoside antibiotics in uremia. N Engl J Med 280:1223–1224
Smith CR, Lietman PS (1983) Effect of furosemide on aminoglycoside-induced nephrotoxicity and auditory toxicity in humans. Antimicrob Agents Chemother 23:133–137
Pillay VKG, Schwartz FD, Aimi K et al (1969) Transient and permanent deafness following treatment with ethacrynic acid in renal failure. Lancet 1:77–79
Meriweather WD, Mangi RJ, Serpick AA (1971) Deafness following standard intravenous doses of ethacrynic acid. JAMA 216:795–798
Cimino MA, Rotstein C, Slaughter RL et al (1987) Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 83:1091–1097
Pauly DJ, Musa DM, Lestico MR et al (1990) Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 10:378382
Mellor JA, Kingdom J, Cafferkey M et al (1985) Vancomycin toxicity: a prospective study. J Antimicrob Chemother 15:773–780
Ryback MJ, Albrecht LM, Boike SC et al (1990) Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 25:679–687
Ramsey TD, Lau TTY, Ensom MHH (2013) Serotonergic and adrenergic drug interactions associated with linezolid: a critical review and practical management approach. Ann Pharmacother 47:543–560
Douros A, Grabowski K, Stahlmann R (2015) Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opin Drug Metab Toxicol 11:1849–1859
Narita M, Tsuji BT, Linezolid-associated YV (2007) Peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 27:1189–1197
Wigen CL, Goetz MB (2002) Serotonin syndrome and linezolid. Clin Infect Dis 34:1651–1652
Hachem RY, Hicks K, Huen A et al (2003) Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. Clin Infect Dis 37:e8–11
Lavery S, Ravi H, McDaniel WW et al (2001) Linezolid and serotonin syndrome. Psychosomatics 42:432–434
Clark DB, Andrus MR, Byrd DC (2006) Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacotherapy 26:269–276
Sola CL, Bostwick JM, Hart DA et al (2006) Anticipating potential linezolid-SSRI interactions in the general hospital setting an MAOI in disguise. Mayo Clin Proc 81:330–334
Aga VM, Barklage NE, Jefferson JW (2003) Linezolid, a monoamine oxidase inhibiting antibiotic, and antidepressants. J Clin Psychiatry 64:609–611
Debellas RJ, Schaefer OP, Liquori M et al (2005) Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazapine in a critically ill bone marrow transplant recipient. J Intensive Care Med 20:303–305
Hammerness P, Parada H, Abrams A (2002) Linezolid: MAOI activity and potential drug interactions. Psychosomatics 43:248–249
Packer S, Berman SA (2007) Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid. Am J Psychiatry 164:346–347
Mason LW, Randhawa KS, Carpenter EC (2008) Serotonin toxicity as a consequence of linezolid use in revision hip arthroplasty. Orthopedics 31:1140
Bergeron L, Boule M, Perreault S (2005) Serotonin toxicity associated with concomitant use of linezolid. Ann Pharmacother 39:956–961
Jones SL, Athan E, O’Brien D (2004) Serotonin syndrome due to co-administration of linezolid and venlafaxine. J Antimicrob Chemother 54:289–290
Steinberg M, Morin A (2007) Mild serotonin syndrome associated with concurrent linezolid and fluoxetine. Am J Health Sys Pharm 64:5962
Lorenz RA, Vandenberg AM, Canepa EA (2008) Serotonergic antidepressants and linezolid: a retrospective chart review and presentation of cases. Int J Psychiatry Med 38:81–90
Das PK, Warkentin DI, Hewko R et al (2008) Serotonin syndrome after concomitant treatment with linezolid with meperidine. Clin Infect Dis 46:264–265
Morrison EK, Rowe AS (2012) Probable drug-drug interaction leading to serotonin syndrome in a patient treated with concomitant buspirone and linezolid in the setting of therapeutic hypothermia. J Clin Pharmacol Ther 37:610–613
Gebhart BC, Barker BC, Markewitz BA (2007) Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 27:476–479
Egle H, Trittler R, Kummerer K et al (2005) Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther 77:451–452
Gervasoni C, Simonetti FR, Resnati C et al (2015) Prolonged inductive effect of rifampicin in linezolid exposure. Eur J Clin Pharmacol 71:643–644
Hendershot PE, Antal EJ, Welshman IR (2002) Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCL, and dextromethorphan HBr. J Clin Pharmacol 41:563–572
Sakai Y, Naito T, Arima C et al (2015) Potential drug interaction between warfarin and linezolid. Intern Med 54:459–464
Bolhuis MS, van Altena R, Uges DRA et al (2010) Clarithromycin significantly increases linezolid serum concentrations. Antimicrob Agents Chemother 54:5418–5419
Bolhuis MS, Altena v, van Soolingen D et al (2013) Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J 42:1614–1621
Synercid IV (2003) (quinupristin-dalfopristin) product information. King Pharmaceutical, Bristol
Stamatakis MK, Richards JG (1997) Interaction between quinupristin-dalfopristin and cyclosporine. Ann Pharmacother 31:576–578
Lampasona V, Crass RE, Reines HD (1983) Decreased serum tobramycin concentrations in patient with renal failure. Clin Pharm 2:6–9
Russo M (1980) Penicillin-aminoglycoside inactivation: another possible mechanism of interaction. Am J Hosp Pharm 37:702–704
Chow MSS, Quintiliani R, Nightingale CH (1982) In vivo inactivation of tobramycin by ticarcillin. JAMA 247:658–659
Kradjan WA, Burger R (1980) In vivo inactivation of gentamicin by carbenicillin and ticarcillin. Arch Intern Med 140:1668–1670
Schentag JJ, Simons GW, Schultz RW et al (1984) Complexation versus hemodialysis to reduce elevated aminoglycoside serum concentrations. Pharmacotherapy 4:374–380
Uber WE, Brundage RR, White RL et al (1991) In vivo inactivation of tobramycin by piperacillin. Ann Pharmacother 25:357–359
Thompson MIB, Russo ME, Saxon BJ et al (1982) Gentamicin inactivation by piperacillin or carbenicillin in patients with end-stage renal disease. Antimicrob Agents Chemother 21:268–273
Ervin FR, Bullock WE, Nuttall CE (1976) Inactivation of gentamicin by penicillins in patients with renal failure. Antimicrob Agents Chemother 9:1004–1031
Wallace SM, Chan LY (1985) In vitro interaction of aminoglycosides with β-lactam penicillins. Antimicrob Agents Chemother 28:274–281
Henderson JL, Polk RE, Kline BJ (1981) In vitro inactivation of gentamicin, tobramycin, and netilmicin by carbenicillin, azlocillin, or mezlocillin. Am J Hosp Pharm 38:1167–1170
Pickering LK, Gearhart P (1979) Effect of time and concentration upon interaction between gentamicin, tobramycin, netilmicin, or amikacin and carbenicillin or ticarcillin. Antimicrob Agents Chemother 15:592–596
Pickering LK, Rutherford I (1981) Effect of concentration and time upon inactivation of tobramycin, gentamicin, netilmicin, and amikacin by azlocillin, carbenicillin, mecillinam, mezlocillin, and piperacillin. J Pharmacol Exp Ther 217:345–349
Hold HA, Broughall JM, McCarthy M et al (1976) Interactions between aminoglycoside antibiotics and carbenicillin or ticarcillin. Infection 4:107–109
Davies M, Morgan JR, Anand C (1975) Interaction of carbenicillin and ticarcillin with gentamicin. Antimicrob Agents Chemother 7:431–434
Mclaughlin JE, Reeves DS (1971) Clinical and laboratory evidence of inactivation of gentamicin by carbenicillin. Lancet 1:261–264
Rich DS (1983) Recent information about inactivation of aminoglycosides by carbenicillin, and ticarcillin: clinical implications. Hosp Pharm 18:41–43
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Susla, G.M. (2018). Miscellaneous Antibiotics. In: Pai, M., Kiser, J., Gubbins, P., Rodvold, K. (eds) Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions. Infectious Disease. Humana Press, Cham. https://doi.org/10.1007/978-3-319-72416-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-72416-4_5
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-72415-7
Online ISBN: 978-3-319-72416-4
eBook Packages: MedicineMedicine (R0)